Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.45 |
| ▸ | FDPS | P14324 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7486685 | 0.93 | TDP1 (0.50) | KDM4EL3MBTL1TDP1PARP1PARP3 | |
| SCHEMBL9632943 | 0.84 | L3MBTL1 (0.53) | KDM4EL3MBTL1TDP1ALDH1A1MAPT | |
| SCHEMBL9633209 | 0.84 | HTR2C (0.52) | KDM4EL3MBTL1TDP1PARP1PARP3 | |
| SCHEMBL9462246 | 0.84 | L3MBTL1 (0.53) | KDM4EL3MBTL1TDP1ALDH1A1MAPT | |
| SCHEMBL9632375 | 0.83 | KDM4E (0.48) | KDM4EL3MBTL1TDP1HTR2A | |
| SCHEMBL9631985 | 0.82 | KCNH2 (0.54) | L3MBTL1TDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL17848587 | 0.82 | L3MBTL1 (0.46) | KDM4EL3MBTL1TDP1ALDH1A1MAPT | |
| SCHEMBL9632875 | 0.82 | L3MBTL1 (0.46) | KDM4EL3MBTL1TDP1ALDH1A1MAPT | |
| SCHEMBL19461858 | 0.82 | L3MBTL1 (0.50) | L3MBTL1TDP1ALDH1A1MAPTMAPK1 | |
| SCHEMBL10263254 | 0.82 | L3MBTL1 (0.50) | KDM4EL3MBTL1TDP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019244066-A2 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-12-26 | — | — | WO | disclosed |
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | UTI LIMITED PARTNERSHIP (CA) | 2016-07-28 | — | — | US | disclosed |
| EP-1068184-B1 | N-ARYLOXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1068184-A1 | N-ARYLOXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6110956-A | ANTIDEPRESSANTS TREATING DISORDERS OF THE SEROTONIN-AFFECTED NEUROLOGICAL SYSTEMS | AMERICAN HOME PRODUCTS CORP. (US) | 2000-08-29 | — | — | US | disclosed |
| WO-1999051576-A1 | N-ARYLOXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0331943-B1 | PHENOXYETHYLAMINE DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND COMPOSITION FOR EXHIBITING EXCELLENT ALPHA-1-BLOCKING ACTIVITY CONTAINING THE SAME | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1992-06-17 | — | — | EP | disclosed |
| US-4971990-A | HYPOTENSIVE AGENTS, DYSUREA | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1990-11-20 | — | — | US | disclosed |
| EP-0331943-A1 | Phenoxyethylamine derivatives, process for preparing the same, and composition for exhibiting excellent alpha-1-blocking activity containing the same | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214973-A1 | STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME | ORAI1, RYR2, CASR | KDM4E 3018/4885L3MBTL1 3268/4885TDP1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.